Regulators Request Contempt Ruling Against Martin Shkreli Over Trading in at Least 60 Drug Companies

The Federal Trade Commission alongside attorneys general from seven separate states have submitted a formal court motion requesting that a federal magistrate hold Martin Shkreli in civil contempt.¹ Enforcement officials argue that the 43-year-old former drug executive repeatedly defied a court-mandated lifetime exclusion barring him from participating in the pharmaceutical business sector.¹ Investigators discovered that Shkreli bought and sold equity stakes across at least 60 distinct pharmaceutical enterprises following his release from federal custody in May 2022.¹ In addition to executing transactions, authorities determined that he routinely aired assessments regarding the daily operations of those enterprises in public settings.¹ Enforcement documents show that these stock purchases and sales allegedly transgressed the detailed restrictions imposed by the federal judiciary during 2022.¹

Regulators established that Shkreli used modern internet platforms, broadcasting his market activity openly across YouTube, Reddit, and X.¹ During one specific video broadcast, he informed his audience that his streams served as educational guides on how to buy, sell, and invest within biotechnology.¹ Federal attorneys contend that he used these live video sessions to mount organized public offensives against selected drug developers.¹ Through these presentations, he reportedly sought to profit from falling prices by shorting specific pharmaceutical equities while broadcasting predictions that their experimental clinical evaluations would fail.¹ During one broadcast presentation, Shkreli insisted that his specific portfolio selections were of little concern because he possessed an unfailing ability to identify biotechnology equities to target.⁴

The binding prohibition central to the current dispute originated from a comprehensive 2022 court ruling regarding an anticompetitive arrangement engineered by Shkreli.¹ That earlier finding proved that he orchestrated an artificial price surge exceeding 5,000% on the medication Daraprim, forcing the per-tablet cost upward from $17.50 to $750.¹ When assessing the case, the presiding judge ordered Shkreli to forfeit $64.6 million in financial penalties.¹ The judicial decision excoriated his commercial misconduct, formally classifying his behavior as deliberate, dangerous, repetitive, egregious, unlawful, and exceptionally long-running.¹ Before his formal release date in 2022, the court permanently prohibited him from ever working within the pharmaceutical marketplace to prevent additional efforts to stifle generic drug rivals.²

The initial government intervention began in January 2020 when the FTC commissioners approved an enforcement lawsuit against Shkreli, another corporate leader, Phoenixus AG, and Vyera Pharmaceuticals LLC by a unanimous tally.⁴ Resolving those claims in 2022, the U.S. District Court for the Southern District of New York found Shkreli liable for fabricating an unlawful monopoly surrounding Daraprim.⁴ That medicine serves as a critical therapeutic intervention deployed by medical providers against toxoplasmosis.⁴ Daniel Guarnera, who leads the Bureau of Competition at the FTC, underlined that Shkreli's monopolistic maneuvering artificially elevated prescription prices for vulnerable patients while preventing low-cost alternative generics from reaching buyers.³ To stop future abuse, the resulting permanent injunction explicitly barred Shkreli from directly or indirectly engaging in the pharmaceutical field, expressly forbidding equity ownership or management meddling.⁴

The civil contempt petition submitted to the court demands extensive remedial measures to strip Shkreli of his recent pharmaceutical activities.¹⁴ Enforcement attorneys specifically demand an order compelling him to divest every single pharmaceutical company share he currently retains in his accounts.⁴ Furthermore, government lawyers want the court to mandate a disgorgement penalty equal to the aggregate trading gains he generated across drug stocks, alongside accrued prejudgment interest.⁴ The plaintiffs specifically insist that this monetary assessment must be calculated without granting Shkreli any credit for trades that produced offsetting investment losses.⁴ The motion also petitions the presiding judge to create an escalating structure of sanctions for upcoming infractions, encompassing expanding fines and possible confinement.⁴

Top legal officers involved in the enforcement filing have voiced strong condemnation of Shkreli's repeated defiance of established court prohibitions.¹ New York Attorney General Letitia James declared that broadcast trading executed by Shkreli breached judicial mandates and the law.¹ James emphasized that his persistent pattern of market manipulation combined with monopolistic strategies imperils public welfare as well as everyday market participants.¹ Weighing in on the enforcement step, FTC Commissioner Mark Meador asserted that lifetime prohibitions preserve regulatory deterrence solely when breaches bring punishments commensurate with judicial authority.³ Agency records reveal that the commission greenlit this current contempt maneuver with a 1-0 roll call following the recusal of FTC Chairman Andrew N. Ferguson.⁴

The ongoing regulatory dispute stands separate from the federal criminal proceedings that had previously sent Shkreli to prison.¹³ A jury originally found him guilty in 2017 on two substantive charges of securities fraud along with one count of conspiracy to commit securities fraud.¹³ Those underlying criminal convictions stemmed from his past stewardship of financial hedge funds as well as an entirely different pharmaceutical corporation.³ Federal authorities subsequently sentenced Shkreli to serve a seven-year term of incarceration during 2018.¹ He exited the federal prison system in May 2022 after authorities applied credit for detention served prior to sentencing alongside other statutory adjustments.¹³

Available evidence indicates that Shkreli now confronts the realistic threat of a return to prison custody under civil contempt rules.¹⁴ This exposure to new incarceration arrives after he already completed a lengthy federal custodial sentence related to his historical securities offenses.¹ Regulators maintain that holding equity positions and offering online commentary regarding at least 60 drug companies direct-market operations violated his lifetime exclusion.¹⁴ The government's filing asks the district court to ensure that court-ordered decrees function as genuine limits rather than voluntary suggestions.¹³⁴

The broad intervention initiated by the FTC and seven state partners highlights an aggressive attempt to police compliance with judicial competition decrees.¹³ Enforcers argue that Shkreli's history of anti-competitive practices surrounding Daraprim justified the total ban and warrants zero tolerance toward subsequent market involvement.¹³⁴ By requesting complete divestment, total forfeiture of trading gains, and escalating contempt penalties, the coalition seeks to strip Shkreli of any capacity to touch drug equities.⁴ The court must now determine whether his post-release online broadcasts and equity shorting warrant imposing severe financial and personal penalties.¹⁴